EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) such as gefitinib, afatinib, and osimertinib represent the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) patients carrying EGFR-activating mutations.